Title:
β3アドレナリン性受容体作動薬としてのアミノアルコール誘導体
Document Type and Number:
Japanese Patent JP2005519951
Kind Code:
A
Abstract:
The present invention relates to a compound formula [I] wherein R1 and R5 are each independently hydrogen, halogen, lower alkyl, etc., R2 is hydrogen or an amino protective group, x is bond, -o-o, -O-CH2-, etc., y is in which Z is bond, -O-(CH2)m- (in which m is 1 to 4), etc., R3 is lower alkanoyl, carboxy, lower alkoxycarbonyl, etc., and R4 is hydrogen, halogen, hydroxy, phenoxy, lower alkyl, lower alkoxy, etc., and n is 0, 1 or 2, or a salt thereof. The compound [I] of the present invention and pharmaceutically acceptable salts thereof are useful for the prophylactic and/or the therapeutic treatment of pollakiurea or urinary incontinence.
Inventors:
Koji Hattori
Yasuyo Tomijima
Yutaka Nakajima
Masashi Imanishi
Yasuyo Tomijima
Yutaka Nakajima
Masashi Imanishi
Application Number:
JP2003574618A
Publication Date:
July 07, 2005
Filing Date:
March 10, 2003
Export Citation:
Assignee:
Fujisawa Pharmaceutical Co., Ltd.
International Classes:
A61K31/18; A61K31/196; A61K31/24; A61K31/245; A61K31/27; A61K31/275; A61K31/341; A61K31/351; A61K31/381; A61K31/402; A61K31/44; A61K31/4406; A61K31/4439; A61K31/445; A61K31/455; A61K31/4965; A61K31/695; A61P1/04; A61P1/16; A61P1/18; A61P3/04; A61P3/06; A61P3/10; A61P5/24; A61P9/10; A61P9/12; A61P13/02; A61P13/04; A61P13/08; A61P13/10; A61P15/00; A61P15/06; A61P25/00; A61P25/02; A61P25/22; A61P25/24; A61P27/06; A61P29/00; C07C217/74; C07C219/26; C07C229/46; C07C229/50; C07C229/60; C07C229/64; C07C233/54; C07C233/55; C07C255/57; C07C255/59; C07C271/24; C07C271/28; C07C275/42; C07C311/08; C07C311/35; C07C311/37; C07C311/51; C07C317/44; C07C321/30; C07C323/62; C07D207/27; C07D211/60; C07D211/62; C07D213/36; C07D213/38; C07D213/40; C07D213/61; C07D213/64; C07D213/643; C07D213/79; C07D213/80; C07D241/24; C07D307/54; C07D307/68; C07D309/12; C07D295/14; C07D309/14; C07D333/22; C07D333/32; C07D333/38; C07D333/40; C07D401/04; C07D405/12; C07F7/18; C07D207/26; (IPC1-7): C07C217/74; A61K31/18; A61K31/196; A61K31/24; A61K31/245; A61K31/27; A61K31/275; A61K31/341; A61K31/351; A61K31/381; A61K31/402; A61K31/44; A61K31/4406; A61K31/4439; A61K31/445; A61K31/455; A61K31/4965; A61K31/695; A61P1/04; A61P1/16; A61P1/18; A61P3/04; A61P3/06; A61P3/10; A61P5/24; A61P9/10; A61P9/12; A61P13/02; A61P13/04; A61P13/08; A61P13/10; A61P15/00; A61P15/06; A61P25/00; A61P25/02; A61P25/22; A61P25/24; A61P27/06; A61P29/00; C07C229/46; C07C229/50; C07C229/60; C07C229/64; C07C233/54; C07C233/55; C07C255/57; C07C255/59; C07C271/24; C07C271/28; C07C275/42; C07C311/35; C07C311/37; C07C317/44; C07C321/30; C07D207/27; C07D211/62; C07D213/36; C07D213/38; C07D213/61; C07D213/64; C07D213/79; C07D213/80; C07D241/24; C07D295/14; C07D307/68; C07D309/12; C07D309/14; C07D333/22; C07D333/32; C07D333/40; C07D401/04; C07F7/18
Attorney, Agent or Firm:
Eiji Tafushi